Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome

CONTEXT: Peptide receptor radionuclide therapy (PRRT) with [Lutetium-177-DOTA(0)-Tyr(3)]octreotate ((177)Lu-DOTATATE) results in an increase of progression-free survival and quality of life in patients with progressive, well-differentiated neuroendocrine neoplasms (NENs). OBJECTIVE: To study the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Zandee, Wouter T, Brabander, Tessa, Blažević, Anela, Minczeles, Noémie S, Feelders, Richard A, de Herder, Wouter W, Hofland, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372632/
https://www.ncbi.nlm.nih.gov/pubmed/33942075
http://dx.doi.org/10.1210/clinem/dgab289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372632/
https://www.ncbi.nlm.nih.gov/pubmed/33942075
http://dx.doi.org/10.1210/clinem/dgab289

Ejemplares similares